专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

121. 发明申请

US20150265716A1 Nanoparticles For Targeted Delivery of Multiple Therapeutic Agents and Methods of Use 有权
标题翻译：用于靶向递送多种治疗剂的纳米颗粒和使用方法
公开(公告)号：US20150265716A1
公开(公告)日：2015-09-24
申请号：US14434300
申请日：2013-10-09
申请人： The Brigham and Women's Hospital, Inc. , Massachusetts Institute of Technology
发明人： Pedro M. Valencia , Eric M. Pridgen , Suresh Gadde , Rohit Karnik , Robert S. Langer , Stephen J. Lippard , Omid C. Farokhzad
IPC分类号： A61K47/48 , A61K31/4745 , A61K47/34 , A61K9/14 , A61K45/06 , A61K33/24 , A61K9/51
CPC分类号： A61K47/6937 , A61K9/14 , A61K9/51 , A61K9/5146 , A61K9/5153 , A61K31/4745 , A61K31/555 , A61K33/24 , A61K45/06 , A61K47/34 , A61K47/593 , A61K47/6869 , B82Y5/00 , A61K2300/00
摘要： Provided herein are compositions that contain a nanoparticle containing a plurality of polymers, wherein at least a fraction of the polymers comprise a hydrophobic polymer, a topoisomerase inhibitor, and a Pt-containing chemotherapeutic agent, where the polymers self-assemble in an aqueous liquid to form the nanoparticle, and where the Pt-containing chemotherapeutic agent and the topoisomerase inhibitor are present within the hydrophobic core of the nanoparticle in a ratio of between about 24:1 to about 1:24. Also provided are methods of reducing the proliferation of a cancer cell and methods of treating cancer in a subject that include the use of these compositions. Also provided are methods of making these nanoparticles.
摘要翻译：本文提供了含有含有多种聚合物的纳米颗粒的组合物，其中至少一部分聚合物包含疏水性聚合物，拓扑异构酶抑制剂和含Pt化学治疗剂，其中聚合物在水性液体中自组装成形成纳米颗粒，并且其中含Pt化学治疗剂和拓扑异构酶抑制剂以约24:1至约1:24的比例存在于纳米颗粒的疏水核心内。还提供了减少癌细胞增殖的方法和在包括使用这些组合物的受试者中治疗癌症的方法。还提供了制备这些纳米颗粒的方法。

122. 发明授权

US09138411B2 Curcumin-ER, a liposomal-PLGA sustained release nanocurcumin for minimizing QT prolongation for cancer therapy 有权
标题翻译：姜黄素ER，脂质体 - PLGA持续释放纳米凝血酶，用于最大限度地减少癌症治疗的QT延长
公开(公告)号：US09138411B2
公开(公告)日：2015-09-22
申请号：US14016056
申请日：2013-08-31
申请人： University of North Texas Health Science Center , SignPath Pharma Inc.
发明人： Amalendu Prakash Ranjan , Anindita Mukerjee , Jamboor K. Vishwanatha , Lawrence Helson
IPC分类号： A61K9/14 , A61K31/12 , A61K9/51 , A61K45/06
CPC分类号： A61K9/145 , A61K9/1271 , A61K9/1277 , A61K9/141 , A61K9/5123 , A61K9/5153 , A61K31/12 , A61K45/06 , A61K47/34
摘要： The present invention includes compositions and methods of making a nanoparticle composition comprising a polymeric core comprising one or more polymers and one or more active agents, and at least one layer of one or more lipids on the surface of the polymeric core; more specifically, the invention relates to the use of curcumin within such a lipid-polymer nanoparticle formulation for minimizing QT prolongation associated with curcumin in treatment of cancer.
摘要翻译：本发明包括制备纳米颗粒组合物的组合物和方法，所述组合物包含聚合物芯，所述聚合物芯包含一种或多种聚合物和一种或多种活性剂，以及聚合物芯表面上的至少一层一种或多种脂质; 更具体地，本发明涉及在这种脂质 - 聚合物纳米颗粒制剂中使用姜黄素以最小化与姜黄素治疗癌症相关的QT延长。

123. 发明申请

US20150216935A1 Autologous Cell-Based Therapy for Treating Obesity 审中-公开
标题翻译：自体基于细胞的治疗肥胖症的治疗
公开(公告)号：US20150216935A1
公开(公告)日：2015-08-06
申请号：US14420600
申请日：2013-08-08
申请人： Brown University
发明人： Edith Mathiowitz , Sasha Bakhru
IPC分类号： A61K38/18 , A61K9/70 , C12N5/077 , A61K35/35 , C12N5/0775 , A61K47/34 , A61K38/28
CPC分类号： A61K38/1858 , A61K9/0024 , A61K9/1647 , A61K9/5153 , A61K9/70 , A61K35/35 , A61K38/18 , A61K38/1841 , A61K38/1875 , A61K38/28 , A61K47/34 , A61L27/18 , A61L27/34 , A61L27/54 , A61L27/56 , A61L27/58 , A61L2300/414 , A61L2430/34 , C12N5/0653 , C12N5/0667 , C12N2501/155 , A61K2300/00 , C08L77/00 , C08L67/04
摘要： Compositions and methods for producing autologous brown adipose cells in vitro or in vivo are provided. In particular, a drug delivery device is described that recruits adipose stem cells (ASCs) to a site in the body of a subject. These ASCs may then be isolated and induced to differentiate into autologous brown adipose cells. Alternatively, the drug delivery device may also include differentiation factors that induce differentiation of the recruited ASCs into brown adipose cells in vivo. The brown adipose cells produced by these methods may be used therapeutically to treat conditions, such as obesity and diabetes.
摘要翻译：提供了在体外或体内产生自体棕色脂肪细胞的组合物和方法。特别地，描述了一种药物递送装置，其将脂肪干细胞（ASCCs）募集到受试者体内的部位。然后可以分离并诱导这些ASC分化成自体棕色脂肪细胞。或者，药物递送装置还可以包括在体内诱导招募的ASC分化成棕色脂肪细胞的分化因子。通过这些方法产生的棕色脂肪细胞可用于治疗性治疗诸如肥胖症和糖尿病的病症。

124. 发明申请

US20150209287A1 Biodegradable Stealth Polymeric Particles Fabricated Using The Macromonomer Approach By Free Radical Dispersion Polymerization 有权
标题翻译：使用自由基分散聚合的大分子单体方法制造的可生物降解的隐形聚合物颗粒
公开(公告)号：US20150209287A1
公开(公告)日：2015-07-30
申请号：US14575517
申请日：2014-12-18
申请人： Howard University
发明人： Emmanuel Oyekanmi Akala , Simeon Kolawole Adesina
IPC分类号： A61K9/16 , A61K31/337 , C08G63/85
CPC分类号： C08G63/78 , A61K9/1635 , A61K9/5153 , A61K31/337 , A61K31/7034 , A61K31/704 , B01J13/06 , B01J13/16 , B82Y5/00 , B82Y15/00 , B82Y40/00 , C08F299/024 , C08G63/06 , C08G63/82 , C08G63/85 , C08G63/912 , Y10S977/773 , Y10T428/2982
摘要： The present invention is directed to a crosslinked or non-crosslinked polymer particle, wherein the crosslinked polymer particle comprises a copolymer of poly(alklyene glycol-graft-lactate) that is crosslinked by at least one hydrolysable monomer. Another embodiment of the present invention is a polymer particle comprising a crosslinked polymer particle that is a product of starting materials comprising (a) a hydrophilic monomer, (b) a hydrophobic monomer, and (c) a hydrolysable crosslinking agent. Another embodiment of the present invention is a polymer particle comprising, a crosslinked copolymer comprises structures represented by Formulas (I), (II), and (III), where Formulas (I), (II) and (III) are defined in the specification. Yet other embodiments of the present invention include a method of preparing a methacrylate terminated macromonomer, a method of preparing a crosslinking agent, and a method of preparing a therapeutic agent loaded nanosphere by dispersion polymerization.
摘要翻译：本发明涉及交联或非交联聚合物颗粒，其中交联聚合物颗粒包含由至少一种可水解单体交联的聚（烷二醇 - 接枝 - 乳酸）共聚物。本发明的另一个实施方案是包含交联聚合物颗粒的聚合物颗粒，其是起始材料的产物，其包含（a）亲水性单体，（b）疏水性单体和（c）可水解交联剂。本发明的另一个实施方案是包含交联共聚物的聚合物颗粒，其包含由式（I），（II）和（III）表示的结构，其中式（I），（II）和（III）规范。本发明的其它实施方案包括制备甲基丙烯酸酯封端的大分子单体的方法，制备交联剂的方法，以及通过分散聚合制备负载纳米球的治疗剂的方法。

125. 发明申请

US20150209284A1 DUAL-TARGETING DRUG CARRIER AND METHOD FOR FABRICATING THE SAME 审中-公开
标题翻译：双重目标药物载体及其制备方法
公开(公告)号：US20150209284A1
公开(公告)日：2015-07-30
申请号：US14271961
申请日：2014-05-07
申请人： National Chung Cheng University
发明人： Yung-Chih KUO , Yu-Hsuan CHANG
IPC分类号： A61K9/14 , A61K47/32 , A61K31/704 , A61K31/7048 , A61K31/17
CPC分类号： A61K31/704 , A61K9/5153 , A61K31/17 , A61K31/7048 , A61K47/551 , A61K47/62 , A61K47/6935 , A61K47/6937
摘要： The present invention discloses a dual-targeting drug carrier and a method for fabricating the same, wherein WGA- and FA-modified MPEG-PLA nanoparticles of the carrier enable the anticancer drugs encapsulated thereinside to pass through BBB and target human glioblastoma cells. The dual-target drug carrier is fabricated in an emulsion-solvent evaporation technology and verified with an in-vitro BBB model formed of HBMECs, HAs and HBVPs. The present invention can increase the permeability of the in-vitro BBB model to the dual-target drug carrier and promote the glioblastoma-inhibition effect. Therefore, the present invention would contribute to the clinical therapy of brain cancers substantially in the future.
摘要翻译：本发明公开了一种双靶向药物载体及其制备方法，其中所述载体的WGA和FA修饰的MPEG-PLA纳米颗粒使得其内包封的抗癌药物能够通过BBB和靶向人成胶质细胞瘤细胞。双靶药物载体以乳液 - 溶剂蒸发技术制造，并用由HBMEC，HAs和HBVP形成的体外BBB模型验证。本发明可以增加体外BBB模型对双靶药物载体的渗透性，促进成胶质细胞瘤抑制作用。因此，本发明将有助于将来大量临床治疗脑癌。

126. 发明申请

US20150202327A1 MOLECULAR ASSEMBLY USING BRANCHED AMPHIPHILIC BLOCK POLYMER, AND DRUG TRANSPORTATION SYSTEM 有权
标题翻译：使用分支的胶囊聚合物和药物运输系统的分子装配
公开(公告)号：US20150202327A1
公开(公告)日：2015-07-23
申请号：US14425429
申请日：2013-09-03
申请人： SHIMADZU CORPORATION , KYOTO UNIVERSITY
发明人： Isao Hara , Eiichi Ozeki , Shunsaku Kimura , Akira Makino
IPC分类号： A61K49/00 , A61K9/51
CPC分类号： A61K49/0054 , A61K9/5153 , A61K47/50 , A61K47/51 , A61K47/593 , A61K49/0034 , A61K49/0089 , A61K49/12 , A61K49/124 , A61K51/0404 , A61K51/06
摘要： The present invention provides a molecular assembly whose retention time in a target site is adjusted depending on the kind or purpose of a labeling agent or drug encapsulated therein, and a molecular assembly that can suppress the ABC phenomenon and that can be administered more than once within a short span. A molecular assembly comprising: a branched-type amphiphilic block polymer A comprising a branched hydrophilic block comprising sarcosine and a hydrophobic block comprising a polylactic acid chain; and a functional substance F comprising a functional site and a polylactic acid chain, wherein the polylactic acid chain constituting the hydrophobic block of the amphiphilic block polymer A comprises L-lactic acid units, and the polylactic acid chain contained in the functional substance F comprises D-lactic acid units, or the polylactic acid chain constituting the hydrophobic block of the amphiphilic block polymer A comprises D-lactic acid units, and the polylactic acid chain contained in the functional substance F comprises L-lactic acid units.
摘要翻译：本发明提供一种分子组合物，其取决于包封在其中的标记试剂或药物的种类或目的在靶位点的保留时间，以及可抑制ABC现象并且可以多次施用的分子组装短跨度一种分子组合物，其包含：支链型两亲嵌段聚合物A，其包含含有肌氨酸的支链亲水嵌段和包含聚乳酸链的疏水嵌段; 和包含功能部位和聚乳酸链的功能性物质F，其中构成所述两亲性嵌段聚合物A的疏水性嵌段的聚乳酸链包含L-乳酸单元，所述功能性物质F中所含的聚乳酸链包含D 或者构成两亲性嵌段聚合物A的疏水性嵌段的聚乳酸链包含D-乳酸单元，功能性物质F中所含的聚乳酸链包含L-乳酸单元。

127. 发明申请

US20150141414A1 Formulation of Stable Recombinant Alpha-Fetoprotein Conjugated with Anti-Tumor Substance in Target-Delivery System for Treatment of Cancer and Autoimmune Disease 审中-公开
标题翻译：在用于治疗癌症和自身免疫疾病的靶向递送系统中制备与抗肿瘤物质结合的稳定的重组甲胎蛋白
公开(公告)号：US20150141414A1
公开(公告)日：2015-05-21
申请号：US14455249
申请日：2014-08-08
申请人： Nana Legrand
发明人： Nana Legrand
IPC分类号： A61K47/48 , A61K47/34 , C07K14/47 , A61K31/538
CPC分类号： C07K14/4715 , A61K9/19 , A61K9/5153 , A61K31/538 , A61K47/26
摘要： Disclosed is a stable formulation based on rAFP conjugated with drug delivery system of various classes of pharmacological agents such as dactinomycin, cardionolide, and bufadinolide, among others. In another embodiment, the invention discloses a method of producing rAFP in a strain of methylotrophic Pichia pastoris yeast, allowing the yeast to replicate, and extracting the newly created rAFP. The method provides a nonpyrogenic, highly stable, recombinant, fully refolded rAFP and its fragments that are free from stable folding intermediates caused by non-native disulfide bridges and irreversible aggregates. The newly created rAFP is purified using a two-step chromatographic purification process in the presence of 0.5% polysorbate-20 and 10 mM inosine that prevents aggregation of the monomers of the target protein, increasing the yield of biologically active rAFP. The invented formulation of rAFP is conjugated with active pharmacological substances or target drug delivery system for prevention or treatment of oncological and autoimmune-diseases.
摘要翻译：公开了一种基于与药物递送系统结合的rAFP的稳定制剂，所述药物递送系统包括各种类型的药理学试剂，例如放线菌素，cardionolide和bufadinolide等。在另一个实施方案中，本发明公开了一种在甲基营养型巴斯德毕赤酵母菌株中生产rAFP的方法，允许酵母复制并提取新产生的rAFP。该方法提供非致死性，高度稳定，重组，完全重折叠的rAFP及其片段，其不含由非天然二硫键和不可逆聚集体引起的稳定折叠中间体。在0.5％聚山梨醇酯-20和10mM肌苷存在下，使用两步色谱纯化方法纯化新产生的rAFP，以防止靶蛋白单体的聚集，提高生物活性rAFP的产量。本发明的rAFP制剂与活性药理物质或靶药物递送系统结合，用于预防或治疗肿瘤和自身免疫疾病。

128. 发明申请

US20150140106A1 OCULAR NANOFORMULATION AND METHOD OF USE IN ANGIOGENESIS-MEDIATED DISORDERS 审中-公开
标题翻译：血管生成介导的疾病中的OCULAR NANOFORMULATION和使用方法
公开(公告)号：US20150140106A1
公开(公告)日：2015-05-21
申请号：US14526738
申请日：2014-10-29
申请人： Shaker A. Mousa
发明人： Shaker A. Mousa
IPC分类号： A61K9/50 , A61K45/06 , A61K47/48 , A61K31/727 , A61K9/00
CPC分类号： A61K9/5036 , A61K9/0048 , A61K9/5026 , A61K9/5146 , A61K9/5153 , A61K9/5161 , A61K31/727 , A61K45/06 , A61K47/6933
摘要： An ophthalmic formulation that includes nanoparticles. Each nanoparticle includes a shell which encapsulates sulfated non-anticoagulant heparin (SNACH), with or without hydrophobic anti-angiogenesis Tyrosine Kinase inhibitors. The SNACH is ionically or covalently bonded to the shell. The shell includes a polymer selected from the group consisting of poly (lactic-co-glycolic acid) (PLGA), chitosan, chitosan-alginate, and NIPAAM-APMAH-AA, wherein NIPAAM is N-isopropyl acrylamide, APMAH is N-3-aminopropylmethacrylamide hydrochloride, and AA is acrylic acid. A method for treating an eye disease of a subject includes: administering to an eye of the subject a therapeutically effective amount of the ophthalmic formulation for treating the eye disease. The eye disease involves an ocular angiogenesis-mediated disorder.
摘要翻译：包括纳米颗粒的眼用制剂。每个纳米颗粒包括封装硫酸化非抗凝血剂肝素（SNACH）的壳，具有或不具有疏水性抗血管生成酪氨酸激酶抑制剂。 SNACH离子或共价键合到壳上。壳包括选自聚（乳酸 - 共 - 乙醇酸）（PLGA），壳聚糖，壳聚糖 - 藻酸盐和NIPAAM-APMAH-AA的聚合物，其中NIPAAM是N-异丙基丙烯酰胺，APMAH是N-3 氨基丙基甲基丙烯酰胺盐酸盐，AA是丙烯酸。用于治疗受试者的眼睛疾病的方法包括：向患者的眼睛施用治疗有效量的用于治疗眼睛疾病的眼用制剂。眼病涉及眼血管生成介导的病症。

129. 发明申请

US20150139906A1 SURFACE-MODIFIED NANOPARTICLES FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS AND COMPOSITIONS FOR MAKING SAME 审中-公开
标题翻译：用于细胞内递送治疗药物和组合物制备的表面改性纳米颗粒
公开(公告)号：US20150139906A1
公开(公告)日：2015-05-21
申请号：US14513613
申请日：2014-10-14
申请人： Board of Regents of the University of Nebraska
发明人： Vinod Labhasetwar , Jaspreet Vasir
IPC分类号： A61K9/51
CPC分类号： A61K9/5153 , A61K9/5138 , A61K9/5146 , Y10S977/773 , Y10S977/906
摘要： Surface-modified polymeric nanoparticles (NPs), compositions for making them, and their use in drug delivery are disclosed.
摘要翻译：公开了表面改性聚合物纳米颗粒（NP），用于制备它们的组合物及其在药物递送中的用途。

130. 发明授权

US09034347B2 Drug delivery system and method for the treatment of neuro-degenerative disease 有权
标题翻译：药物输送系统和治疗神经退行性疾病的方法
公开(公告)号：US09034347B2
公开(公告)日：2015-05-19
申请号：US13720157
申请日：2012-12-19
申请人： Aphios Corporation
发明人： Trevor Percival Castor , Jonathan Steven Alexander , Geoffrey Purdum , J. David Rios , Lisa M. Schrott , Theodore A. Tyler , Maria I. Vizcaino
IPC分类号： A61K9/16 , A61K9/48 , A61K9/51 , A61K31/365
CPC分类号： A61K9/5153 , A61K9/16 , A61K9/4858 , A61K31/365
摘要： Embodiments of the present invention are directed to the oral administration of Bryostatins for the treatment of neuro-degenerative disease.
摘要翻译：本发明的实施方案涉及用于治疗神经退行性疾病的苔藓抑素的口服给药。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式